

Brief Curriculum Vitae (CV)

Name Georgios Chamilos

Place of birth/date of birth Heraklion/Crete/20/02/1973

Home Address Machis Kritis 125, Heraklion, Crete, 71303

Phone +30-2810-328059

E-mail: hamilos@imbb.forth.gr, hamilos@uoc.gr

Present Affiliation

Associate Professor of Parasitology, Head of Clinical Microbiology and Microbial Pathogenesis Department, School of Medicine, University of Crete (3/2016)

Affiliated Investigator with the Institute of Molecular Biology and Biotechnology (IMBB), Heraklion, Crete (12/2010-Present)

Affiliated Faculty with Department of Internal Medicine and Infectious Diseases, School of Medicine, University of Crete (05/2016)

Previous Affiliation

Attending Physician, Department of Internal Medicine, Heraklion University Hospital, Crete, (09/2010-3/2016)

Office Address

Host Defense and Fungal Pathogenesis Lab Room #3D72, Clinical Microbiology and Microbial Pathogenesis Department, School of Medicine, University of Crete, 71003, Heraklion, Crete

Phone +30-2810-394560

Fax +30-2810-394626

Education

Graduate Education

University of Athens, Medical School 1990-1996.

Postgraduate Education

Marie Curie Postdoctoral Research Fellow, the Institute of Molecular Biology and Biotechnology (IMBB), Heraklion, Crete
12/2010 - 12/2014

Postdoctoral Research fellow, The University of Crete, Department of Internal Medicine, 06/2009 - 09/2010

Advanced Infectious Diseases/Immunology Fellow, The University of Texas Health Science Center at Houston Medical School, Houston, TX, 07/2008 - 04/2009

Clinical Fellow in Infectious Diseases, The University of Texas Health Science Center at Houston Medical School, Houston, TX, 07/2006 - 7/2008

Research fellow, The University of Texas M.D. Anderson Cancer Center, Department of Infectious Diseases, Mycology Research Unit, 05/2004 – 05/2006

Doctoral thesis, Therapeutics Clinic, Medical School, University of Athens 01/2003 - 07/2007

Internal Medicine Resident, University of Athens, Department of Therapeutics, Alexandra General Hospital of Athens, Athens, Greece, 01/2000 - 11/2003

Internal Medicine Resident, General Hospital of Sitia, Crete, 09/1999 – 01/2000.

Internal Medicine Resident, 251 Air Force General Hospital, 09/1998 - 07/1999

Second Lieutenant of the Medical Corp of Air Force, 11/1997 - 07/1999

Intern, Ierapetra General Hospital, 09/1996 - 09/1997.

Credentials

Greek Board of Internal Medicine #7337, 3/15/2004

Medical License: Active, #33978, 8/27/1996

ECFMG Certificate, 2007

Honors/Awards:

Ranked at the **99th** percentile position in the United States Medical Licensure Exam (USMLE) Step 2 (2003)

Ranked at the **97th** percentile position in the United States Medical Licensure Exam (USMLE) Step 1 (2003)

1st place winner of the Bristol-Myers Squibb Award in Clinical/Translational Research for the abstract “*Drosophila melanogaster* as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in *Candida*”, 9th Trainee Recognition Day, The University of Texas M. D. Anderson Cancer Center (2005)

1st place winner of Research Poster Competition: (Lionakis MS, Chamilos G and Kontoyiannis DP) Pentamidine has activity in a neutropenic murine model of acute invasive pulmonary fusariosis. American College of Physicians (ACP) Associates Day 2006, Texas Academy of Internal Medicine (TAIM), Clear Lake City, TX, USA, 2006.

Winner (one of the two recipients) of *The Kimberly Patterson Fellowship in Leukemia Research* award, The University of Texas M. D. Anderson Cancer Center (2007)

1st place winner, basic research poster competition, 2nd Infections in Cancer Symposium for “*Drosophila melanogaster* as a model host to dissect the immunopathogenesis of zygomycosis”, Houston, TX, USA, 2008

Marie Curie Reintegration Grant (260210, FLY-FUNGAL INTERPLAY): Dissecting innate immunity to airborne opportunistic fungi through a genome-wide screen in *Drosophila*, (EU contribution 100, 000 €, 48 months) (2010)

Aristeia Grant (co-investigator), (MARS-CARS), Macrophage Responses in Compensatory Anti-inflammatory Response Syndrome (ESPA, 200,000€, 48 months) (2014)

Winner for Best Abstract Submission, “Noncanonical autophagy is a target of fungal cell wall melanin” (Oral Presentation, Akoumianaki T., Chamilos G.), 6th Advances Against Aspergillosis, Madrid, 27/2-1/3/2014

FP7-2009-REGPOT-1 (co-investigator). Enhancing Regional Potential and Scientific Excellence through Translational Research in Major Diseases).

Merieux Institute Advanced Research Grant, Exploring the role of LC3 associated phagocytosis in sepsis induced immunosuppression (100, 000 € 24 months), 2015

Research Programs for Excellence IKY/Siemens, 2015-2017 (Exploring Novel Mechanisms of Killing of “Persister” Mucorales candida inside Macrophages, Supervisor of PhD Student Aggeliki Andrianaki, 32,000 € 24 months)

Ad Hoc Reviewer

Scientific Journals

Cell Host and Microbe
Frontiers in Cellular and Infection Microbiology
Journal of Investigation Dermatology
Antimicrobial Agents Chemotherapy
Journal of Antimicrobial Chemotherapy
Journal of Infectious Diseases
Medical Mycology
Mycoses

Professional Memberships

Cretan Medical Society
Member of Infectious Diseases Society of America
Member of Faculty of 1000, Field: Mycology

C. Invited Lectures

1. Departmental Research Seminar Meeting, Department of Infectious Diseases, Infection Control & Employee Health, The University of Texas M. D. Anderson Cancer Center, “*Drosophila melanogaster* as an alternative in vivo model to study candidiasis.” 01/05.
2. University of Crete, Invited Lectures. “Mini-host models of fungal infections”, 07/07
3. University of Crete, Department of Pediatrics, Host Response to Infection: a course for clinicians “Dendritic cells and Infection” 07/09
4. School of Biological and Chemical Sciences, Queen Mary University of London, “*Drosophila melanogaster* as a model to dissect immunopathogenesis of zygomycosis” 7/09
5. 2nd Immunology Summer School and Conference, Fiskardo, Kefalonia. “Innate sensing of antimicrobial peptide-DNA complexes”. 08/09
6. University of Oxford Department of Biochemistry “*Drosophila* as a model of immunopathogenesis of fungal infections” 10/09
7. 8th Hellenic Conference in Immunology, Athens “Dendritic cells regulate fungal pathogenicity via the induction of the Th17 responses”. 12/2010
8. 3rd Immunology Summer School and Conference, Spetes, Greece. “Recent advances in immunity to fungal pathogens” 7/2011
9. Gordon Research Conference, Immunity of fungal Infections, January 13-18, 2013, Galveston, TX, USA. Dissecting the role of autophagy in immunity against *Aspergillus*.
10. 3rd International Forum on Zygomycosis, September 19-21, 2014, Athens. Practical approach to the diagnosis and treatment of mucormycosis: An educational course.
11. Gordon Research Conference, Immunity of fungal Infections, January 18-23, 2015, Galveston, TX, USA. Cell wall melanin regulates fungal pathogenicity via targeting noncanonical autophagy
12. Autophagy in Health and Disease, April 7-10, 2015, Braga, Portugal. The emerging role of LC3 associated phagocytosis in antifungal immunity
13. Plenary lecturer: Seventh Lecture Course on Human Fungal pathogens-Host-pathogen interactions, the host perspective (FEBS lectures), 2017, Nice, France
14. Chair: Galveston GRC, fungal immunology meeting January 15-20 Chair: Immune-Metabolic Interactions In Fungal Immunity
15. Plenary lecturer, Galveston GRC, fungal immunology meeting January 15-20 Novel Pathways regulating fungal phagosome biogenesis

Publications

1. Dimopoulos MA, **Hamilos G**. Solitary bone plasmacytoma and extramedullary plasmacytoma. *Curr Treat Options Oncol*. 2002. 3; 255-9.
2. Dimopoulos MA, Zervas C, Zomas A, **Hamilos G**, Gika D, Efstathiou E, Panayiotidis P, Vervessou E, Anagnostopoulos N, Christakis J. Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia. *Clin Lymphoma*. 2002. 3; 163-6.

3. Dimopoulos MA, Tsatalas C, Zomas A, **Hamilos G**, Panayiotidis P, Margaritis D, Matsouka C, Economopoulos T, Anagnostopoulos N. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. *Semin Oncol*. 2003. 30; 265-9.
4. Economopoulos T, Fountzilas G, Pavlidis N, Kalantzis D, Papageorgiou E, Christodoulou C, **Hamilos G**, Nicolaides C, Dimopoulos M. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. *Hematol J*. 2003. 4; 110-5.
5. Dimopoulos MA, **Hamilos G**, Efstathiou E, Siapkarakas I, Matsouka C, Gika D, Grigoraki V, Papadimitriou C, Mitsibounas D, Anagnostopoulos N. Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. *Leuk Lymphoma*. 2003. 44; 993-6.
6. Dimopoulos MA, **Hamilos G**, Zervas K, Symeonidis A, Kouvatseas G, Roussou P, Gika D, Karmiris T, Bourantas K, Zomas A, Mitsouli C, Xilouri I, Vervessou E, Matsis K, Anagnostopoulos N, Economopoulos T; Greek Myeloma Study Group. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. *Ann Oncol*. 2003. 14; 1299-305.
7. Dimopoulos MA, **Hamilos G**, Zomas A, Gika D, Efstathiou E, Grigoraki V, Poziopoulos C, Xilouri I, Zorzou MP, Anagnostopoulos N, Anagnostopoulos A. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. *Hematol J*. 2004; 5; 112-7
8. Anagnostopoulos A, **Hamilos G**, Zorzou MP, Grigoraki V, Anagnostou D, Dimopoulos MA. Discordant response or progression in patients with myeloma treated with thalidomide-based regimens. *Leuk Lymphoma*. 2004. 45; 113-6.
9. Papadimitriou CA, Markaki S, Siapkarakas J, Vlachos G, Efstathiou E, Grimani I, **Hamilos G**, Zorzou M, Dimopoulos MA. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. *Oncology*. 2004. 66; 112-7.
10. Anagnostopoulos A, Gika D, **Hamilos G**, Zervas K, Zomas A, Pouli A, Zorzou M, Kastritis E, Anagnostopoulos N, Tassidou A, Anagnostou D, Dimopoulos MA. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors. *Leuk Lymphoma*. 2004. 45; 2275-9.
11. Dimopoulos MA, Papadimitriou C, **Hamilos G**, Efstathiou E, Vlahos G, Rodolakis A, Aravantinos G, Kalofonos H, Kouroussis C, Gika D, Skarlos D, Bamias A. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. *Gynecol Oncol*. 2004 95; 695-700.
12. Bamias A, Efstathiou E, Mouloupoulos LA, Gika D, **Hamilos G**, Zorzou MP, Kakoyiannis C, Kastritis E, Bozas G, Papadimitriou C, Dimopoulos MA. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. *Ann Oncol*. 2005; 16:307-13.
13. Kontoyiannis DP, Lionakis MS, Lewis RE, **Chamilos G**, Healy M, Perego C, Safdar A, Kantarjian H, Champlin G, Walsh TJ, Raad II. Zygomycosis in the era of *Aspergillus*-active therapy in a tertiary care cancer center: A matched case-control observational study of 27 recent patients. *J Infect Dis* 2005; 193:1350-1360.
14. **Chamilos G***, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E, Papadimitriou C, Dimopoulos MA. Outpatient treatment of low-risk neutropenic fever in cancer patients, with oral moxifloxacin. *Cancer* 2005; 103:2629-2635

15. **Chamilos G**, Kontoyiannis DP. Voriconazole-resistant disseminated *Paecilomyces variotii* infection in a neutropenic patient with leukemia on voriconazole prophylaxis. *Journal of Infection*, 2005. 51:e225-228.
16. Binu JV, **Chamilos G**, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. *Clin Microbiol Infect*, 2005; 11: 515-517.
17. Chamilos G, Marom E, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in cancer patients. *Clin Infect Dis* 2005; 41:60-66.
18. Chamilos G, Lionakis MS, Lewis RE, Lopez-Ribot JL, Saville SP, Albert ND, Halder G, Kontoyiannis DP. *Drosophila melanogaster* as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in *Candida*. *J Infect Dis*, 2006, 193:1014-1022
19. Lionakis MS, Lewis RE, **Chamilos G**, Kontoyiannis DP. Lack of correlation of *in vitro* susceptibility testing of *Aspergillus* spp. with outcome of initial amphotericin B-based therapy in cancer patients with invasive aspergillosis. *Pharmacotherapy*; 2005; 25: 1174-1180.
20. **Chamilos G**, Lewis RE, and Kontoyiannis DP. Lovastatin has significant activity against Zygomycetes and interacts synergistically with voriconazole. *Antimicrob Agents Chemother* 2006; 50:96-103.
21. **Chamilos G**, Lewis RE, Kontoyiannis DP. Inhibition of *Candida parapsilosis*, mitochondrial respiratory pathways enhances susceptibility to caspofungin. *Antimicrob Agents Chemother*. 2006; 50:744-747.
22. Lionakis MS[†], **Chamilos G**[†], Lewis RE, Wiederhold NP, Raad II, Samonis G, Kontoyiannis DP. Pentamidine has activity in a neutropenic murine model of acute invasive pulmonary fusariosis. *Antimicrob Agents Chemother* 2006; 50:294-297.
23. Kumashi PR, Safdar A, **Chamilos G**, Chemaly RF, Raad II, Kontoyiannis DP. Fungal osteoarticular infections in patients treated at a comprehensive cancer center: a 10-year retrospective review. *Clin Microbiol Infect*; 2006; 12:621-626.
24. Kontoyiannis DP, **Chamilos G**, Hassan SA, Lewis RE, Albert ND, Tarrand JJ. Increased culture recovery of Zygomycetes under physiologic temperature conditions. *Am J Clin Pathol*; 2007; 127:208-212.
25. **Chamilos G**, Luna M, Lewis RE, Bodey GP, Chemaly R, Safdar A, Tarrand JJ, Raad II, Kontoyiannis DP. Invasive fungal infections in patients with hematological malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). *Haematologica* 2006; 91:986-989
26. **Chamilos G**, Kontoyiannis DP. Update on resistance mechanisms in *Aspergillus fumigatus*. *Drug Resistance Updates*, 2005; 193:1014-1022.
27. **Chamilos G**, Kontoyiannis DP. Defining the diagnosis of invasive aspergillosis. *Med Mycology*. 2006 ; (44Suppl) : 163-72.
28. **Chamilos G**, Kontoyiannis DP. The rationale for combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine. *Curr Opin Infect Dis* 2006; 19:380-385.
29. **Chamilos G**, Lewis RE, Kontoyiannis DP. Multidrug-resistant endosymbiotic bacteria account for the emergence of zygomycosis: a hypothesis. *Fungal Genetics Biol* 2007; 44:88-92.
30. **Chamilos G**, Lionakis MS, Lewis RE, Kontoyiannis DP. The emerging role of mini-host models in the study of medically important fungi *Lancet Infect Dis* 2007; 7:42-55.
31. Lamarinis GA, **Chamilos G**, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporiosis in a tertiary care cancer center: a review of 25 cases. *Clin Infect Dis* 2006; 43:1580-1584.

32. Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, **Chamilos G**, Palella F, Kennedy L, Mullane K, Tallman MS, Evens A, Scheetz MH, Blum W, Kontoyiannis DP. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. *Bone Marrow Transplantation* 2007; 39(7): 425-9.
33. Lewis RE, Liao G, Hou J, **Chamilos G**, Prince RA, Kontoyiannis DP. A Comparative Analysis of Amphotericin B Lipid Complex and Liposomal Amphotericin B Kinetics of Lung Accumulation and Fungal Clearance in a Murine Model of Acute Invasive Pulmonary Aspergillosis. *Antimicrob Agents Chemother* 2007; 51: 1253-8.
34. Lewis RE, **Chamilos G**, Prince RA, Kontoyiannis DP. Pre-treatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. *Antimicrob Agents Chemother* 2007; 51(3):1078-81.
35. Spikes S, Xu R, Nguyen CK, **Chamilos G**, Kontoyiannis DP, Jacobson RH, Ejzykowicz DE, Chiang LY, Filler SG, May GS. Gliotoxin production in *Aspergillus fumigatus* contributes to host specific differences in virulence. *J Infect Dis* 2008; 197: 479-86.
36. **Chamilos G**, Macapinlac HA, Kontoyiannis DP. The prospects of [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in diagnosis and management of invasive mold infections (IMIs). *Med Mycol* 2007; 46: 23-9.
37. Kontoyiannis DP, **Chamilos G**, Lewis RE, Giralt S, Cortes J, Raad II, Manning JT, Han X. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematological malignancies and recipients of allogeneic hematopoietic stem cell transplants. *Cancer* 2007; 15: 1303-6.
38. **Chamilos G**, Lewis RE, Albert N, Kontoyiannis DP. The paradoxical effect of echinocandins across *Candida* species in vitro: evidence for echinocandin-specific and *Candida* species-specific related differences. *Antimicrob Agents Chemother* 2007; 51: 2257-59.
39. **Chamilos G**, Luna M, Lewis RE, Chemaly R, Raad II, Kontoyiannis DP. Liver histopathology in patients with hematologic malignancy and invasive fungal infections treated with liposomal amphotericin B vs. amphotericin B lipid complex: An autopsy study. *Clin Therapeut* 2007; 29: 1980-6.
40. Lamaris G, **Chamilos G**, Lewis RE, Kontoyiannis DP. Virulence studies of *Scedosporium* and *Fusarium* spp. in *Drosophila melanogaster*. *J Infect Dis* 2007; 196: 1860-4.
41. **Chamilos G**, Lewis RE, Lamaris G, TJ Walsh, Kontoyiannis DP. *Zygomycetes* hyphae trigger an early, robust pro-inflammatory response in human polymorphonuclear neutrophils through Toll like receptor-2 induction but display relative resistance to oxidative damage. *Antimicrob Agents Chemother*, 2008; 52: 722-724.
42. Lamaris GA, Esmali B, **Chamilos G**, Desai A, Chemaly RF, Raad II, Safdar A, Lewis RE, Kontoyiannis DP. Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases. *Eur J Clin Microbiol Infect Dis*, 2008; 27: 243-247.
43. **Chamilos G**, Lewis RE, Lamaris GA, Albert ND, Kontoyiannis DP. Genome-wide screening for genes associated with gliotoxin resistance in *Saccharomyces cerevisiae*. *Antimicrob Agents Chemother*. 2008, 52: 1325-1329.
44. Lamaris GA, Lewis RE, **Chamilos G**, Walsh TJ, May GS, Safdar A, Raad II, Kontoyiannis DP. Caspofungin-mediated β -glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against *Aspergillus* and non-*Aspergillus* molds. *J Infect Dis*, 2008; 198:186-192.

45. **Chamilos G**, Lewis RE, Hu J, Xiao L, Zal T, Gilliet M, Halder G, Kontoyiannis DP. *Drosophila melanogaster* as a model host to dissect the immunopathogenesis of zygomycosis. *Proceedings of National Academy of Sciences, USA*, 2008; 105:9367-9372.
46. **Chamilos G**, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based front-line therapy significantly increases mortality in hematologic malignancy patients with zygomycosis. *Clin Infect Dis*, 2008; 503-509.
47. Ibrahim AS, Gebremariam T, Liu M, **Chamilos G**, Kontoyiannis DP, J. Khown-Chung, Y. Fu, C. Skory, J.E. Edwards, Jr, B.J. Spellberg. Bacterial endosymbiosis does not contribute to mucormycosis pathogenesis. *J Infect Dis*, 2008; 198:1083-1090.
48. Lamarinis GA, Ben-Ami R, Lewis RE, **Chamilos G**, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. *J Infect Dis*, 2009; 199:1399-1406.
49. **Chamilos G**, Bignell EM, Schrettl M, Lewis RE, May GS, Haas H, Kontoyiannis DP. Exploring the concordance of *Aspergillus fumigatus* Pathogenicity between *Toll* deficient flies and mice. *Med Mycol*, 2010; 48: 506-510.
50. **Chamilos G**, Nobile CJ, Bruno MV, Lewis RE, Mitchell AP, Kontoyiannis DP. *C. albicans* cell wall integrity regulator Cas5 promotes virulence in murine and *Toll*-mutant fly models. *J Infect Dis*; 2009; 200:152-157.
51. Ganguly D, **Chamilos G**, Lande R, Gregorio J, Meller S, Facchinetti V, Homey B, Barrat F, Zal T, Gilliet M. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and 8. *J Exp Med* 2009; 206: 1983-1994.
52. **Chamilos G**, Ganguly D, Lande R, Gregorio J, Meller S, Goldman GE, Gilliet M, Kontoyiannis DP. β -glucan cell wall exposure induces IL-23-producing DCs and drives T_H17 responses to airborne opportunistic fungi. *PLoS One* 2010; 5:e12955.
53. Lande R, Ganguly D, Facchinetti V, Gregorio J, Frasca L, Conrad C, **Chamilos G**, Sebasigari R, Riccieri V, Bassett R, Amuro H, Fukuhara S, Liu YJ, Ito T, Gilliet M. Neutrophils release DNA-antimicrobial peptide complexes that activate pDC and trigger autoimmunity in SLE. *Sci Trans Med* 2011; 3:73ra19
54. **Chamilos G**, Samonis G, Kontoyiannis DP. Recent Advances in the Use of *Drosophila melanogaster* as a Model to Study Immunopathogenesis of Medically Important Filamentous Fungi. *Int J Microbiol*. 2012.
55. **Chamilos G**, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis. *Semin Respir Crit Care Med*. 2011, 32:693-702.
56. Pongas G, **Chamilos G**, Rolston KV, Kontoyiannis DP. Formal adult infectious disease specialist consultations in the outpatient setting at a comprehensive cancer center (1998-2008): diverse and impactful. *Support Care Cancer*. 2012; 20:261-5.
57. **Chamilos G**, Gregorio J, Meller S, Lande R, Kontoyiannis DP, Modlin RL, Gilliet M. Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. *Blood* 2012; 120:3699-707
58. **Chamilos G**, Samonis G, Kontoyiannis DP. *Drosophila melanogaster* as a Model Host for the Study of microbial pathogenicity and the discovery of novel antimicrobial compounds. *Curr Pharm Des*. 2011; 17:1246-53
59. Smeekens SP, Conway KL, Gresnigt MS, Begun J, Plantinga TS, Joosten LAB., van der Meer JWM, **Chamilos G**, Netea MG, Xavier RJ, van de Veerdonk FL. Defective autophagy underlies inflammation in chronic granulomatous disease. *Proceedings of National Academy of Sciences, USA*, 2014; 111:3526-31

60. Kyrmizi I, Gresnigt MS, Akoumianaki T, Samonis G, Sidiropoulos P, Boumpas D, Netea MG, van de Veerdonk FL, Kontoyiannis DP, **Chamilos G***,# . Corticosteroids Block Autophagy Protein Recruitment in *Aspergillus fumigatus* Phagosomes via Targeting Dectin-1/Syk Kinase Signaling. *J Immunol*. 2013; 191:1287-99
61. Lewis RE, Cahyame-Zuniga L, Leventakos K, **Chamilos G**, Ben-Ami R, Tamboli P, Tarrand J, Bodey GP, Luna M, Kontoyiannis DP. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. *Mycoses*. 201; 56:638-45.
62. Lewis RE, Georgiadou SP, Sampsonas F, **Chamilos G**, Kontoyiannis DP. Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis. *Mycoses*. 2014 ;57(1):49-55
63. Dimopoulou D, **Hamilos G**, Samonis G, Kontoyiannis DP. Anidulafungin vs Caspofungin in a Mouse Model of Candidiasis Caused by Anidulafungin-Susceptible *C. parapsilosis* Isolates with Different Degrees of Caspofungin Susceptibility. *Antimicrob Agents Chemother*. 2014; 58:229-36
64. Lande R[†], **Georgios Chamilos**[†], Dipyaman Ganguly[†], De Maria O, Frasca L, Conrad C, Schröder J, Gilliet M. Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. *Eur J Immunol*; 2015; 45, 203-213
65. Buffen K, Oosting M, Quintin J, Ng A, Kleinnijenhuis J, Kumar V, van de Vosse E, Wijmenga C, van Crevel R, Oosterwijk E, Grotenhuis AJ, Vermeulen SH, Kiemeneij LA; van de Veerdonk FL, **Chamilos G**, Xavier RJ, van der Meer JWM, Netea MG, Joosten LAB. Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer. *PLoS Pathogens*, 2014; 10(10):e1004485
66. Frasca L, Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, **Chamilos G**, Feldmeyer L, Marinari B, Chon S, Vence L, Ricciari V, Guillaume P, Navarini A, Romero P, Costanzo A, Piccolella E, Gilliet M. The antimicrobial peptide LL37 is a T cell autoantigen in psoriasis. *Nat Commun*. 2014, 5:5621
67. Meller S, Di Dimozio J, **Chamilos G**, Ganguly D, Conrad C, Gregorio J, Voo K, Ladbury JE, Homey B, Liu YJ, Watowich S, Kontoyiannis D, Arold ST, Gilliet M. Interleukin (IL)-26 is an antimicrobial protein that promotes immune sensing of self-nucleic acids. 2013, Submitted (*Nat Immunol*) 2015 (Accepted, *Nat Immunol*, 2015).
68. Maraki S, **Hamilos G**, Dimopoulou D, Andrianaki AM, Karageorgiadis AS, Kyvernitakis A, Lionakis S, Kofteridis DP, Samonis G. Comparative activity of echinocandins on murine gut colonization by *Candida albicans*. *Med Mycol*, 2015
69. Akoumianaki T, Kyrmizi I, Valsecchi I, Gresnigt MS, Samonis G, Drakos E, Boumpas D, Muszkieta L, Prevost MC, Kontoyiannis DP, Chavakis T, Netea MG, van de Veerdonk FL, Brakhage AA, El-Benna J, Beauvais A, Latge JP, **Chamilos G***. *Aspergillus* Cell Wall Melanin Blocks LC3-Associated Phagocytosis to Promote Pathogenicity. *Cell Host Microbe*. 2015 Dec 30. pii: S1931-3128(15)00494-1.
70. Ioannou P, Andrianaki A, Akoumianaki T, Kyrmizi I, Albert N, Perlin D, Samonis G, Kontoyiannis DP, **Chamilos G***. Albumin enhances caspofungin activity against *Aspergillus* species by facilitating drug delivery to germinating hyphae. *Antimicrob Agents Chemother*. 2015 Dec 7. pii: AAC.02026-15.
71. **Klionsky DJ** et al. Guidelines for the use and interpretation of assays for monitoring autophagy (2nd edition). *Autophagy* 2016 No 0, 1-222

72. **Chamilos G***, Akoumianaki T, Kyrmizi I, Brakhage A, Beauvais A, Latge JP. Melanin Targets LC3-associated phagocytosis (LAP): a novel pathogenetic mechanism in fungal disease. *Autophagy*. 2016 [Epub ahead of print]
73. Kyvernitakis A, Torres HA, Jiang Y, **Chamilos G**, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: A propensity score analysis. *Clin Microbiol Infect*. 2016 [Epub ahead of print]
 - * **Corresponding author**
 - † **Contributed equally to this work**
 - # **Featured publication (Editorial Commentary)**

B. Book Chapters

1. **Chamilos G**, Kontoyiannis DP. *Aspergillus*, *Candida*, and other opportunistic mold infections of the lung. Chapter 147. *Fishman's Pulmonary Diseases & Disorders*, 4th edition McGraw-Hill, 2008, and 5th edition (2013)
2. **Chamilos G**, and Kontoyiannis DP. Insect models of infection. In G Goldman & S. Osmani. *The Aspergilli: Genomics, Medicine, Biotechnology and Research methods*. CRC Press; 2007
3. Papadimitraki ED, Bertias G, **Chamilos G**, Boumpas DT. Systemic Lupus Erythematosus: Cytotoxic Agents. *Systemic Lupus Erythematosus*, 5th Edition, Chapter 58. Lahita, Academic Press, 2010